Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 - PubMed (original) (raw)
Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40
E M Sotomayor et al. Nat Med. 1999 Jul.
Abstract
Tumor antigen-specific T-cell tolerance limits the efficacy of therapeutic cancer vaccines. Antigen-presenting cells mediate the induction of T-cell tolerance to self-antigens. We therefore assessed the fate of tumor-specific CD4+ T cells in tumor-bearing recipients after in vivo activation of antigen-presenting cells with antibodies against CD40. Such treatment not only preserved the responsiveness of this population, but resulted in their endogenous activation. Established tumors regressed in vaccinated mice treated with antibody against CD40 at a time when no response was achieved with vaccination alone. These results indicate that modulation of antigen-presenting cells may be a useful strategy for enhancing responsiveness to immunization.
Similar articles
- CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.
Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, Offringa R, Toes RE. Diehl L, et al. Nat Med. 1999 Jul;5(7):774-9. doi: 10.1038/10495. Nat Med. 1999. PMID: 10395322 - Split peripheral tolerance: CD40 ligation blocks tolerance induction for CD8 T cells but not for CD4 T cells in response to intestinal antigens.
Chung Y, Ko SY, Ko HJ, Kang CY. Chung Y, et al. Eur J Immunol. 2005 May;35(5):1381-90. doi: 10.1002/eji.200425819. Eur J Immunol. 2005. PMID: 15827964 - Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.
Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L, Bien H, Borrello IM, Levitsky HI, Sotomayor EM. Cuenca A, et al. Cancer Res. 2003 Dec 15;63(24):9007-15. Cancer Res. 2003. PMID: 14695219 - CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity.
Toes RE, Schoenberger SP, van der Voort EI, Offringa R, Melief CJ. Toes RE, et al. Semin Immunol. 1998 Dec;10(6):443-8. doi: 10.1006/smim.1998.0147. Semin Immunol. 1998. PMID: 9826577 Review. - Controlling autoreactivity of CD4 T cells by local tolerance induction.
Förster I. Förster I. Dev Immunol. 1998;6(1-2):89-94. doi: 10.1155/1998/83953. Dev Immunol. 1998. PMID: 9716909 Free PMC article. Review. No abstract available.
Cited by
- Perspective view of allogeneic IgG tumor immunotherapy.
Liu Y, Huang Y, Cui HW, Wang Y, Ma Z, Xiang Y, Xin HY, Liang JQ, Xin HW. Liu Y, et al. Cancer Cell Int. 2024 Mar 9;24(1):100. doi: 10.1186/s12935-024-03290-9. Cancer Cell Int. 2024. PMID: 38461238 Free PMC article. Review. - Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.
Tang L, Huang Z, Mei H, Hu Y. Tang L, et al. Signal Transduct Target Ther. 2023 Aug 18;8(1):306. doi: 10.1038/s41392-023-01521-5. Signal Transduct Target Ther. 2023. PMID: 37591844 Free PMC article. Review. - Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
Coveler AL, Smith DC, Phillips T, Curti BD, Goel S, Mehta AN, Kuzel TM, Markovic SN, Rixe O, Bajor DL, Gajewski TF, Gutierrez M, Lee HJ, Gopal AK, Caimi P, Heath EI, Thompson JA, Ansari S, Jacquemont C, Topletz-Erickson A, Zhou P, Schmitt MW, Grilley-Olson JE. Coveler AL, et al. J Immunother Cancer. 2023 Jun;11(6):e005584. doi: 10.1136/jitc-2022-005584. J Immunother Cancer. 2023. PMID: 37385724 Free PMC article. Clinical Trial. - Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.
Parker S, McDowall C, Sanchez-Perez L, Osorio C, Duncker PC, Briley A, Swartz AM, Herndon JE 2nd, Yu YA, McLendon RE, Tedder TF, Desjardins A, Ashley DM, Gunn MD, Enterline DS, Knorr DA, Pastan IH, Nair SK, Bigner DD, Chandramohan V. Parker S, et al. Sci Transl Med. 2023 Feb 8;15(682):eabn5649. doi: 10.1126/scitranslmed.abn5649. Epub 2023 Feb 8. Sci Transl Med. 2023. PMID: 36753564 Free PMC article. - Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity.
Pfefferlé M, Dubach IL, Buzzi RM, Dürst E, Schulthess-Lutz N, Baselgia L, Hansen K, Imhof L, Koernig S, Le Roy D, Roger T, Humar R, Schaer DJ, Vallelian F. Pfefferlé M, et al. J Immunother Cancer. 2023 Jan;11(1):e005718. doi: 10.1136/jitc-2022-005718. J Immunother Cancer. 2023. PMID: 36593065 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials